The effects of vitamin D on brain development and adult brain function

Molecular and Cellular Endocrinology

Volumn 347, Issue 1-2, 2011, Pages 121-127

  Kesby, James P ^a   Eyles, Darryl W ^a,b   Burne, Thomas H J ^a,b   McGrath, John J ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QUEENSLAND CENTRE FOR MENTAL HEALTH RESEARCH   (Australia)

Author keywords

Brain; Development; Dopamine; Schizophrenia; Vitamin D

Indexed keywords

CALCITRIOL; CALCIUM; COLECALCIFEROL; PROGESTERONE; VITAMIN D; VITAMIN D RECEPTOR;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN DEVELOPMENT; BRAIN FUNCTION; BRAIN METABOLISM; CALCIUM MOBILIZATION; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOPAMINE RELEASE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEASONAL AFFECTIVE DISORDER; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM;

ADULT; ANIMALS; BRAIN; DOPAMINE; HUMANS; MICE; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RECEPTORS, CALCITRIOL; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 82455162454     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.05.014     Document Type: Review

References (148)

1. Adams J.S., Liu P.T., Chun R., Modlin R.L., Hewison M. Vitamin D in defense of the human immune response. Ann. N.Y. Acad. Sci. 2007, 1117:94-105.
2. Almeras L., Eyles D., Benech P., Laffite D., Villard C., Patatian A., Boucraut J., Mackay-Sim A., McGrath J., Feron F. Developmental vitamin D deficiency alters brain protein expression in the adult rat: implications for neuropsychiatric disorders. Proteomics 2007, 7:769-780.
3. Amato R., Pinelli M., Monticelli A., Miele G., Cocozza S. Schizophrenia and vitamin D related genes could have been subject to latitude-driven adaptation. BMC Evol. Biol. 2010, 10:351.
4. Ambani L.M., Van Woert M.H., Murphy S. Brain peroxidase and catalase in Parkinson disease. Arch. Neurol. 1975, 32:114-118.
5. Amento E.P. Vitamin D and the immune system. Steroids 1987, 49:55-72.
6. Andreasen N.C. Symptoms, signs, and diagnosis of schizophrenia. Lancet 1995, 346:477-481.
7. Annweiler C., Allali G., Allain P., Bridenbaugh S., Schott A.M., Kressig R.W., Beauchet O. Vitamin D and cognitive performance in adults: a systematic review. Eur. J. Neurol. 2009, 16:1083-1089.
8. Baksi S.N., Hughes M.J. Chronic vitamin D deficiency in the weanling rat alters catecholamine metabolism in the cortex. Brain Res. 1982, 242:387-390.
9. Balabanova S., Richter H.P., Antoniadis G., Homoki J., Kremmer N., Hanle J., Teller W.M. 25-Hydroxyvitamin D, 24, 25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D in human cerebrospinal fluid. Klin. Wochenschr. 1984, 62:1086-1090.
10. Banerjee P., Chatterjee M. Antiproliferative role of vitamin D and its analogs - a brief overview. Mol. Cell. Biochem. 2003, 253:247-254.
11. Bernd P. The role of neurotrophins during early development. Gene Expr. 2008, 14:241-250.
12. Bertone-Johnson E.R. Vitamin D and the occurrence of depression: causal association or circumstantial evidence?. Nutr. Rev. 2009, 67:481-492.
13. Borges M.C., Martini L.A., Rogero M.M. Current perspectives on vitamin D, immune system, and chronic diseases. Nutrition 2011, 27:399-404.
14. Brewer L.D., Thibault V., Chen K.C., Langub M.C., Landfield P.W., Porter N.M. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J. Neurosci. 2001, 21:98-108.
15. Brown J., Bianco J.I., McGrath J.J., Eyles D.W. 1,25-Dihydroxyvitamin D-3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci. Lett. 2003, 343:139-143.
16. Brown S.J. The role of vitamin D in multiple sclerosis. Ann. Pharmacother. 2006, 40:1158-1161.
17. Buell J.S., Dawson-Hughes B., Scott T.M., Weiner D.E., Dallal G.E., Qui W.Q., Bergethon P., Rosenberg I.H., Folstein M.F., Patz S., Bhadelia R.A., Tucker K.L. 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology 2010, 74:18-26.
18. Burket R., McGrath J., Eyles D. Vitamin D receptor expression in the embryonic rat brain. Neurosci. Res. Commun. 2003, 33:63-71.
19. Burne T.H., Becker A., Brown J., Eyles D.W., Mackay-Sim A., McGrath J.J. Transient prenatal Vitamin D deficiency is associated with hyperlocomotion in adult rats. Behav. Brain Res. 2004, 154:549-555.
20. Burne T.H., McGrath J.J., Eyles D.W., Mackay-Sim A. Behavioural characterization of vitamin D receptor knockout mice. Behav. Brain Res. 2005, 157:299-308.
21. Burne T.H., O'Loan J., McGrath J.J., Eyles D.W. Hyperlocomotion associated with transient prenatal vitamin D deficiency is ameliorated by acute restraint. Behav. Brain Res. 2006, 174:119-124.
22. Burne T.H.J., Johnston A.N.B., McGrath J.J., Mackay-Sim A. Swimming behaviour and post-swimming activity in Vitamin D receptor knockout mice. Brain Res. Bull. 2006, 69:74-78.
23. Cantor-Graae E., Selten J.P. Schizophrenia and migration: a meta-analysis and review. Am J Psychiat 2005, 162:12-24.
24. Cass W.A., Smith M.P., Peters L.E. Calcitriol protects against the dopamine- and serotonin-depleting effects of neurotoxic doses of methamphetamine. Ann. N.Y. Acad. Sci. 2006, 1074:261-271.
25. Cekic M., Sayeed I., Stein D.G. Combination treatment with progesterone and vitamin D hormone may be more effective than monotherapy for nervous system injury and disease. Front. Neuroendocrinol. 2009, 30:158-172.
26. Chao M.V. The p75 neurotrophin receptor. J. Neurobiol. 1994, 25:1373-1385.
27. Chapuy M.C., Preziosi P., Maamer M., Arnaud S., Galan P., Hercberg S., Meunier P.J. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos. Int. 1997, 7:439-443.
28. Chiu K.Y., Pun W.K., Luk K.D., Chow S.P. Sequential fractures of both hips in elderly patients - a prospective study. J. Trauma 1992, 32:584-587.
29. Christakos S., Dhawan P., Liu Y., Peng X.R., Porta A. New insights into the mechanisms of vitamin D action. J. Cell. Biochem. 2003, 88:695-705.
30. Chun H.S., Yoo M.S., DeGiorgio L.A., Volpe B.T., Peng D., Baker H., Peng C., Son J.H. Marked dopaminergic cell loss subsequent to developmental, intranigral expression of glial cell line-derived neurotrophic factor. Exp. Neurol. 2002, 173:235-244.
31. Clemens T.L., Adams J.S., Henderson S.L., Holick M.F. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1982, 1:74-76.
32. Clemens T.L., Garrett K.P., Zhou X.Y., Pike J.W., Haussler M.R., Dempster D.W. Immunocytochemical localization of the 1,25-dihydroxyvitamin D3 receptor in target cells. Endocrinology 1988, 122:1224-1230.
33. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192:481-483.
34. Cui X.Y., McGrath J.J., Burne T.H.J., Mackay-Sim A., Eyles D.W. Maternal vitamin D depletion alters neurogenesis in the developing rat brain. Int. J. Dev. Neurosci. 2007, 25:227-232.
35. Cui X.Y., Pelekanos M., Burne T.H.J., McGrath J.J., Eyles D.W. Maternal vitamin D deficiency alters the expression of genes involved in dopamine specification in the developing rat mesencephalon. Neurosci. Lett. 2010, 486:220-223.
36. Davies G., Welham J., Chant D., Torrey E.F., McGrath J. A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. Schizophr. Bull. 2003, 29:587-593.
37. Delisi L.E. The significance of age of onset for schizophrenia. Schizophr. Bull. 1992, 18:209-215.
38. Derex L., Trouillas P. Reversible parkinsonism, hypophosphoremia, and hypocalcemia under vitamin D therapy. Mov. Disord. 1997, 12:612-613.
39. Dicou E. Neurotrophins and neuronal migration in the developing rodent brain. Brain Res. Rev. 2009, 60:408-417.
40. Dusso A.S., Brown A.J., Slatopolsky E. Vitamin D. Am. J. Physiol. Renal Physiol. 2005, 289:F8-F28.
41. Erben R.G., Soegiarto D.W., Weber K., Zeitz U., Lieberherr M., Gniadecki R., Moller G., Adamski J., Balling R. Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. Mol. Endocrinol. 2002, 16:1524-1537.
42. Evatt M.L., Delong M.R., Khazai N., Rosen A., Triche S., Tangpricha V. Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Arch. Neurol. 2008, 65:1348-1352.
43. Eyles D., Brown J., Mackay-Sim A., McGrath J., Feron F. Vitamin D-3 and brain development. Neuroscience 2003, 118:641-653.
44. Eyles D.W., Smith S., Kinobe R., Hewison M., McGrath J.J. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J. Chem. Neuroanat. 2005, 29:21-30.
45. Eyles D.W., Rogers F., Buller K., McGrath J.J., Ko P., French K., Burne T.H. Developmental vitamin D (DVD) deficiency in the rat alters adult behaviour independently of HPA function. Psychoneuroendocrinology 2006, 31:958-964.
46. Eyles D.W., Cui X., Kesby J.P., Harms L.H., Ko P., McGrath J.J., Burne T.H. Developmental vitamin D deficiency causes abnormal brain development. Psychoneuroendocrinology 2009, S247-S257.
47. Feron F., Burne T.H.J., Brown J., Smith E., McGrath J.J., Mackay-Sim A., Eyles D.W. Developmental Vitamin D-3 deficiency alters the adult rat brain. Brain Res. Bull. 2005, 65:141-148.
48. Fu G.K., Lin D., Zhang M.Y.H., Bikle D.D., Shackleton C.H.L., Miller W.L., Portale A.A. Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol. Endocrinol. 1997, 11:1961-1970.
49. Garcion E., Sindji L., Montero-Menei C., Andre C., Brachet P., Darcy F. Expression of inducible nitric oxide synthase during rat brain inflammation: regulation by 1,25-dihydroxyvitamin D3. Glia 1998, 22:282-294.
50. Garcion E., Sindji L., Leblondel G., Brachet P., Darcy F. 1,25-Dihydroxyvitamin D3 regulates the synthesis of gamma-glutamyl transpeptidase and glutathione levels in rat primary astrocytes. J. Neurochem. 1999, 73:859-866.
51. Gates M.A., Torres E.M., White A., Fricker-Gates R.A., Dunnett S.B. Re-examining the ontogeny of substantia nigra dopamine neurons. Eur. J. Neurosci. 2006, 23:1384-1390.
52. Gloth F.M., Alam W., Hollis B. Vitamin D vs broad spectrum phototherapy in the treatment of seasonal affective disorder. J. Nutr. Health Aging 1999, 3:5-7.
53. Grant W.B. Does vitamin D reduce the risk of dementia?. J. Alzheimers Dis. 2009, 17:151-159.
54. Griffin M.D., Xing N., Kumar R. Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu. Rev. Nutr. 2003, 23:117-145.
55. Grisso J.A., Kelsey J.L., Strom B.L., Chiu G.Y., Maislin G., O'Brien L.A., Hoffman S., Kaplan F. Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group. N. Engl. J. Med. 1991, 324:1326-1331.
56. Gumireddy K., Ikegaki N., Phillips P.C., Sutton L.N., Reddy C.D. Effect of 20-epi-1 alpha,25-dihydroxyvitamin D-3 on the proliferation of human neuroblastoma: role of cell cycle regulators and the Myc-Id2 pathway. Biochem. Pharmacol. 2003, 65:1943-1955.
57. Holick M.F. Environmental factors that influence the cutaneous production of vitamin D. Am. J. Clin. Nutr. 1995, 61:638S-645S.
58. Holick M.F. Vitamin D deficiency. N. Engl. J. Med. 2007, 357:266-281.
59. Hollis B.W., Wagner C.L. Vitamin D deficiency during pregnancy: an ongoing epidemic. Am. J. Clin. Nutr. 2006, 84:273.
60. Hooks M.S., Kalivas P.W. The role of mesoaccumbens pallidal circuitry in novelty-induced behavioral activation. Neuroscience 1995, 64:587-597.
61. Hultman C.M., Sparen P., Takei N., Murray R.M., Cnattingius S. Prenatal and perinatal risk factors for schizophrenia, affective psychosis, and reactive psychosis of early onset: case-control study. Br. Med. J. 1999, 318:421-426.
62. Hypponen E., Laara E., Reunanene A., Jarvelin M.R., Virtanen S.M. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001, 358:1500-1503.
63. Ibi M., Sawada H., Nakanishi M., Kume T., Katsuki H., Kaneko S., Shimohama S., Akaike A. Protective effects of 1 alpha,25-(OH)(2)D-3 against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacology 2001, 40:761-771.
64. Johnell O., Melton L.J., Atkinson E.J., O'Fallon W.M., Kurland L.T. Fracture risk in patients with parkinsonism: a population-based study in Olmsted County, Minnesota. Age Ageing 1992, 21:32-38.
65. Jorde R., Sneve M., Figenschau Y., Svartberg J., Waterloo K. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. J. Intern. Med. 2008, 264:599-609.
66. Kalueff A., Loseva E., Haapasalo H., Rantala I., Keranen J., Lou Y.R., Minasyan A., Keisala T., Miettinen S., Kuuslahti M., Tuchirnaa P. Thalamic calcification in vitamin D receptor knockout mice. NeuroReport 2006, 17:717-721.
67. Kalueff A.V., Lou Y.R., Laaksi L., Tuohimaa P. Increased anxiety in mice lacking vitamin D receptor gene. NeuroReport 2004, 15:1271-1274.
68. Kalueff A.V., Tuohimaa P. Neurosteroid hormone vitamin D and its utility in clinical nutrition. Curr. Opin. Clin. Nutr. Metab. Care 2007, 10:12-19.
69. Keisala T., Minasyan A., Jarvelin U., Wang J.H., Hamalainen T., Kalueff A.V., Tuohimaa P. Aberrant nest building and prolactin secretion in vitamin D receptor mutant mice. J. Steroid Biochem. Mol. Biol. 2007, 104:269-273.
70. Keisala T., Minasyan A., Lou Y.R., Zou J., Kalueff A.V., Pyykko I., Tuohimaa P. Premature aging in vitamin D receptor mutant mice. J. Steroid Biochem. Mol. Biol. 2009, 115:91-97.
71. Kesby J.P., Burne T.H.J., McGrath J.J., Eyles D.W. Developmental vitamin D deficiency alters MK 801-induced hyperlocomotion in the adult rat: an animal model of schizophrenia. Biol. Psychiatry 2006, 60:591-596.
72. Kesby J.P., Cui X., Ko P., McGrath J.J., Burne T.H., Eyles D.W. Developmental vitamin D deficiency alters dopamine turnover in neonatal rat forebrain. Neurosci. Lett. 2009, 461:155-158.
73. Kesby J.P., Cui X., O'Loan J., McGrath J.J., Burne T.H.J., Eyles D.W. Developmental vitamin D deficiency alters dopamine-mediated behaviors and dopamine transporter function in adult female rats. Psychopharmacology 2010, 159-168.
74. Kholodilov N., Yarygina O., Oo T.F., Zhang H., Sulzer D., Dauer W., Burke R.E. Regulation of the development of mesencephalic dopaminergic systems by the selective expression of glial cell line-derived neurotrophic factor in their targets. J. Neurosci. 2004, 24:3136-3146.
75. Kim J.S., Kim Y.I., Song C., Yoon I., Park J.W., Choi Y.B., Kim H.T., Lee K.S. Association of vitamin D receptor gene polymorphism and Parkinson's disease in Koreans. J. Korean Med. Sci. 2005, 20:495-498.
76. Ko P., Burkert R., McGrath J., Eyles D. Maternal vitamin D-3 deprivation and the regulation of apoptosis and cell cycle during rat brain development. Brain Res. Dev. Brain Res. 2004, 153:61-68.
77. Korsching S., Auburger G., Heumann R., Scott J., Thoenen H. Levels of nerve growth factor and its mRNA in the central nervous system of the rat correlate with cholinergic innervation. EMBO J. 1985, 4:1389-1393.
78. Kurtzke J.F., Goldberg I.D. Parkinsonism death rates by race, sex, and geography. Neurology 1988, 38:1558-1561.
79. Lansdowne A.T.G., Provost S.C. Vitamin D-3 enhances mood in healthy subjects during winter. Psychopharmacology 1998, 135:319-323.
80. Lauder J.M., Bloom F.E. Ontogeny of monoamine neurons in locus coeruleus, raphe nuclei and substantia nigra of rat. 1: Cell-differentiation. J. Comp. Neurol. 1974, 155:469-481.
81. Levi-Montalcini R., Caramia F., Luse S.A., Angeletti P.U. In vitro effects of the nerve growth factor on the fine structure of the sensory nerve cells. Brain Res. 1968, 8:347-362.
82. Liao P.C., Kuo Y.M., Hsu H.C., Cherng C.G., Yu L. Local proteins associated with methamphetamine-induced nigrostriatal dopaminergic neurotoxicity. J. Neurochem. 2005, 95:160-168.
83. Lin L.F.H., Doherty D.H., Lile J.D., Bektesh S., Collins F. Gdnf - a glial-cell line derived neurotrophic factor for midbrain dopaminergic-neurons. Science 1993, 260:1130-1132.
84. Llewellyn D.J., Lang I.A., Langa K.M., Muniz-Terrera G., Phillips C.L., Cherubini A., Ferrucci L., Melzer D. Vitamin D and risk of cognitive decline in elderly persons. Arch. Intern. Med. 2010, 170:1135-1141.
85. Looker A.C., Gunter E.W. Hypovitaminosis D in medical inpatients. N. Engl. J. Med. 1998, 339:344-345.
86. Lux W.E., Kurtzke J.F. Is Parkinson's disease acquired? Evidence from a geographic comparison with multiple sclerosis. Neurology 1987, 37:467-471.
87. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., Evans R.M. The nuclear receptor superfamily - the 2nd decade. Cell 1995, 83:835-839.
88. Marini F., Bartoccini E., Cascianelli G., Voccoli V., Baviglia M.G., Magni M.V., Garcia-Gil M., Albi E. Effect of 1alpha,25-dihydroxyvitamin D3 in embryonic hippocampal cells. Hippocampus 2010, 20:696-705.
89. Mathieu C., van Etten E., Decallonne B., Guilietti A., Gysemans C., Bouillon R., Overbergh L. Vitamin D and 1,25-dihydroxyvitamin D3 as modulators in the immune system. J. Steroid Biochem. Mol. Biol. 2004, 89-90:449-452.
90. Matkovits T., Christakos S. Ligand occupancy is not required for vitamin-D-receptor and retinoid receptor-mediated transcriptional activation. Mol. Endocrinol. 1995, 9:232-242.
91. May H.T., Bair T.L., Lappe D.L., Anderson J.L., Horne B.D., Carlquist J.F., Muhlestein J.B. Association of vitamin D levels with incident depression among a general cardiovascular population. Am. Heart J. 2010, 159:1037-1043.
92. McCann J.C., Ames B.N. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction?. FASEB J. 2008, 22:982-1001.
93. McGrath J. Universal interventions for the primary prevention of schizophrenia. Aust. N.Z. J. Psychol. 2000, 34:S58-S64.
94. McGrath J., Feron F., Eyles D., Mackay-Sim A. Vitamin D: the neglected neurosteroid?. Trends Neurosci. 2001, 24:570-571.
95. McGrath J.J., Kimlin M.G., Saha S., Eyles D.W., Parisi A.V. Vitamin D insufficiency in south-east Queensland. Med. J. Aust. 2001, 174:150-151.
96. McGrath J., Eyles D., Mowry B., Yolken R., Buka S. Low maternal vitamin D as a risk factor for schizophrenia: a pilot study using banked sera. Schizophr. Res. 2003, 63:73-78.
97. McGrath J.J., Welham J.L. Season of birth and schizophrenia: a systematic review and meta-analysis of data from the Southern Hemisphere. Schizophr. Res. 1999, 35:237-242.
98. McGrath J.J., Saari K., Hakko H., Jokelainen J., Jones P.B., Jarvelin M.R., Chant D.C., Isohanni M. Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth-cohort study. Schizophr. Res. 2004, 67:16.
99. McGrath J., Iwazaki T., Eyles D., Burne T., Cui X., Ko P., Matsumoto I. Protein expression in the nucleus accumbens of rats exposed to developmental vitamin D deficiency. PLoS ONE 2008, 3:e2383.
100. McGrath J.J., Burne T.H., Feron F., Mackay-Sim A., Eyles D.W. Developmental vitamin D deficiency and risk of schizophrenia: a 10-year update. Schizophr. Bull. 2010, 36:1073-1078.
101. McGrath J.J., Eyles D.W., Pedersen C.B., Anderson C., Ko P., Burne T.H., Norgaard-Pedersen B., Hougaard D.M., Mortensen P.B. Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study. Arch. Gen. Psychiatry 2010, 67:889-894.
102. Merlino L.A., Curtis J., Mikuls T.R., Cerhan J.R., Criswell L.A., Saag K.G. Vitamin D intake is inversely associated with rheumatoid arthritis - results from the Iowa Women's Health Study. Arthritis Rheum. 2004, 50:72-77.
103. Minasyan A., Keisala A., Lou Y.R., Kalueff A.V., Tuohimaa P. Neophobia, sensory and cognitive functions, and hedonic responses in vitamin D receptor mutant mice. J. Steroid Biochem. Mol. Biol. 2007, 104:274-280.
104. Munger K.L., Zhang S.M., O'Reilly E., Hernan M.A., Olek M.J., Willett W.C., Ascherio A. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004, 62:60-65.
105. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA J. Am. Med. Assoc. 2006, 296:2832-2838.
106. Naveilhan P., Neveu I., Baudet C., Ohyama K.Y., Brachet P., Wion D. Expression of 25(Oh) vitamin-D-3 24-hydroxylase gene in glial-cells. NeuroReport 1993, 5:255-257.
107. Naveilhan P., Neveu I., Baudet C., Funakoshi H., Wion D., Brachet P., Metsis M. 1,25-Dihydroxyvitamin D3 regulates the expression of the low-affinity neurotrophin receptor. Brain Res. Mol. Brain Res. 1996, 41:259-268.
108. Naveilhan P., Neveu I., Wion D., Brachet P. 1,25-Dihydroxyvitamin D-3, an inducer of glial cell line-derived neurotrophic factor. NeuroReport 1996, 7:2171-2175.
109. Neveu I., Naveilhan P., Baudet C., Brachet P., Metsis M. 1,25-Dihydroxyvitamin D3 regulates NT-3, NT-4 but not BDNF mRNA in astrocytes. NeuroReport 1994, 6:124-126.
110. Neveu I., Naveilhan P., Jehan F., Baudet C., Wion D., De Luca H.F., Brachet P. 1,25-Dihydroxyvitamin D3 regulates the synthesis of nerve growth factor in primary cultures of glial cells. Brain Res. Mol. Brain Res. 1994, 24:70-76.
111. Neveu I., Naveilhan P., Menaa C., Wion D., Brachet P., Garabedian M. Synthesis of 1,25-dihydroxyvitamin D3 by rat brain macrophages in vitro. J. Neurosci. Res. 1994, 38:214-220.
112. Newmark H.L., Newmark J. Vitamin D and Parkinson's disease - a hypothesis. Mov. Disord. 2007, 22:461-468.
113. O'Loan J., Eyles D.W., Kesby J., Ko P., McGrath J.J., Burne T.H. Vitamin D deficiency during various stages of pregnancy in the rat; its impact on development and behaviour in adult offspring. Psychoneuroendocrinology 2007, 32:227-234.
114. Perry T.L., Yong V.W. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 1986, 67:269-274.
115. Prufer K., Veenstra T.D., Jirikowski G.F., Kumar R. Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the rat brain and spinal cord. J. Chem. Neuroanat. 1999, 16:135-145.
116. Puchacz E., Stumpf W.E., Stachowiak E.K., Stachowiak M.K. Vitamin D increases expression of the tyrosine hydroxylase gene in adrenal medullary cells. Brain Res. Mol. Brain Res. 1996, 36:193-196.
117. Sanchez B., Relova J.L., Gallego R., Ben-Batalla I., Perez-Fernandez R. 1,25-Dihydroxyvitamin D-3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum. J. Neurosci. Res. 2009, 87:723-732.
118. Saporito M.S., Wilcox H.M., Hartpence K.C., Lewis M.E., Vaught J.L., Carswell S. Pharmacological induction of nerve growth factor mRNA in adult rat brain. Exp. Neurol. 1993, 123:295-302.
119. Sato Y., Kikuyama M., Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology 1997, 49:1273-1278.
120. Sato Y., Honda Y., Iwamoto J., Kanoko T., Satoh K. Abnormal bone and calcium metabolism in immobilized Parkinson's disease patients. Mov. Disord. 2005, 20:1598-1603.
121. Sayeed I., Stein D.G. Progesterone as a neuroprotective factor in traumatic and ischemic brain injury. Prog. Brain Res. 2009, 175:219-237.
122. Schneider B., Weber B., Frensch A., Stein J., Fritze J. Vitamin D in schizophrenia, major depression and alcoholism. J. Neural Transm. 2000, 107:839-842.
123. Seeman P., Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975, 188:1217-1219.
124. Shinpo K., Kikuchi S., Sasaki H., Moriwaka F., Tashiro K. Effect of 1,25-dihydroxyvitamin D(3) on cultured mesencephalic dopaminergic neurons to the combined toxicity caused by l-buthionine sulfoximine and 1-methyl-4-phenylpyridine. J. Neurosci. Res. 2000, 62:374-382.
125. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., Marsden C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 1994, 36:348-355.
126. Smidt M.P., Burbach J.P. How to make a mesodiencephalic dopaminergic neuron. Nat. Rev. Neurosci. 2007, 8:21-32.
127. Smith M.P., Fletcher-Turner A., Yurek D.M., Cass W.A. Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. Neurochem. Res. 2006, 31:533-539.
128. 3 in brain and spinal cord. Neuroendocrinol. Lett. 1980, 2:297-301.
129. Stumpf W.E., O'Brien L.P. 1,25 (OH)2 vitamin D3 sites of action in the brain. An autoradiographic study. Histochemistry 1987, 87:393-406.
130. Sutherland M.K., Somerville M.J., Yoong L.K., Bergeron C., Haussler M.R., McLachlan D.R. Reduction of vitamin D hormone receptor mRNA levels in Alzheimer as compared to Huntington hippocampus: correlation with calbindin-28k mRNA levels. Brain Res. Mol. Brain Res. 1992, 13:239-250.
131. Taghizadeh M., Djazayery A., Salami M., Eshraghian M.R., Zavareh S.A.T. Vitamin-D-free regimen intensifies the spatial learning deficit in Alzheimer's disease. Int. J. Neurosci. 2011, 121:16-24.
132. Taniura H., Ito M., Sanada N., Kurarnoto N., Ohno Y., Nakamichi N., Yoneda Y. Chronic vitamin D-3 treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons. J. Neurosci. Res. 2006, 83:1179-1189.
133. Tekes K., Gyenge M., Folyovich A., Csaba G. Influence of neonatal vitamin A or vitamin D treatment on the concentration of biogenic amines and their metabolites in the adult rat brain. Horm. Metab. Res. 2009, 41:277-280.
134. Tekes K., Gyenge M., Hantos M., Csaba G. Transgenerational hormonal imprinting caused by vitamin A and vitamin D treatment of newborn rats. Alterations in the biogenic amine contents of the adult brain. Brain Dev. 2009, 31:666-670.
135. Tenenhouse A., Warner M., Commissiong J.W. Neurotransmitters in the Cns of the Vitamin-D deficient, hypocalcemic rat. Neurochem. Int. 1991, 18:249-255.
136. Torrey E.F., Bowler A.E., Clark K. Urban birth and residence as risk factors for psychoses: an analysis of 1880 data. Schizophr. Res. 1997, 25:169-176.
137. Torrey E.F., Miller J. Season of birth and schizophrenia: southern hemisphere data. Aust. N.Z. J. Psychiatry 1997, 31:308-309.
138. Veenstra T.D., Prufer K., Koenigsberger C., Brimijoin S.W., Grande J.P., Kumar R. 1,25-Dihydroxyvitamin D-3 receptors in the central nervous system of the rat embryo. Brain Res. 1998, 804:193-205.
139. Vieth R., Cole D.E., Hawker G.A., Trang H.M., Rubin L.A. Wintertime vitamin D insufficiency is common in young Canadian women, and their vitamin D intake does not prevent it. Eur. J. Clin. Nutr. 2001, 55:1091-1097.
140. Voorn P., Kalsbeek A., Jorritsmabyham B., Groenewegen H.J. The prenatal and postnatal-development of the dopaminergic cell groups in the ventral mesencephalon and the dopaminergic innervation of the striatum of the rat. Neuroscience 1988, 25:857-887.
141. Wang J.Y., Wu J.N., Cherng T.L., Hoffer B.J., Chen H.H., Borlongan C.V., Wang Y. Vitamin D-3 attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res. 2001, 904:67-75.
142. Wang Y., Chiang Y.H., Su T.P., Hayashi T., Morales M., Hoffer B.J., Lin S.Z. Vitamin D-3 attenuates cortical infarction induced by middle cerebral arterial ligation in rats. Neuropharmacology 2000, 39:873-880.
143. Weinberger D.R. Implications of normal brain-development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 1987, 44:660-669.
144. Wilkins C.H., Sheline Y.L., Roe C.M., Birge S.J., Morris J.C. Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am. J. Geriatr. Psychiatry 2006, 14:1032-1040.
145. Wion D., MacGrogan D., Neveu I., Jehan F., Houlgatte R., Brachet P. 1,25-Dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis. J. Neurosci. Res. 1991, 28:110-114.
146. Zehnder D., Bland R., Williams M.C., McNinch R.W., Howie A.J., Stewart P.M., Hewison M. Extrarenal expression of 25-hydroxyvitamin D-3-1 alpha-hydroxylase. J. Clin. Endocrinol. Metab. 2001, 86:888-894.
147. Zhang J., Sokal I., Peskind E.R., Quinn J.F., Jankovic J., Kenney C., Chung K.A., Millard S.P., Nutt J.G., Montine T.J. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol. 2008, 129:526-529.
148. Zou J., Minasyan A., Keisala T., Zhang Y., Wang J.H., Lou Y.R., Kalueff A., Pyykko I., Tuohimaa P. Progressive hearing loss in mice with a mutated vitamin D receptor gene. Audiol. Neurootol. 2008, 13:219-230.